DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Micardis HCT (Telmisartan / Hydrochlorothiazide) - Summary

 
 



USE IN PREGNANCY

When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus. When pregnancy is detected, MICARDIS HCT tablets should be discontinued as soon as possible (see WARNINGS, Fetal/Neonatal Morbidity and Mortality).

 

MICARDIS HCT SUMMARY

MICARDIS® HCT (telmisartan/hydrochlorothiazide) is a combination of telmisartan, an orally active angiotensin II antagonist acting on the AT1 receptor subtype, and hydrochlorothiazide, a diuretic.

MICARDIS® HCT (telmisartan/hydrochlorothiazide) is indicated for the treatment of hypertension. This fixed dose combination is not indicated for initial therapy (see DOSAGE AND ADMINISTRATION).
See all Micardis HCT indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Micardis HCT (Telmisartan / Hydrochlorothiazide)

Gis map details program aimed at increasing hypertension education using barbershops
Source: Hypertension News From Medical News Today [2014.07.24]
Heart disease and stroke are the second and fourth leading causes of death among black men in the Mississippi Delta region.

Screening for undiagnosed hypertension via electronic health records
Source: Hypertension News From Medical News Today [2014.07.20]
A new study authored by Northwestern Medicine® researchers found that reviewing electronic health records (EHRs) using algorithms can successfully identify patients with previously undiagnosed...

Treatment-resistant hypertension requires proper diagnosis
Source: Hypertension News From Medical News Today [2014.07.09]
High blood pressure - also known as hypertension - is widespread, but treatment often fails. One in five people with hypertension does not respond to therapy.

Hypertension, antihypertension medication and risk of psoriasis
Source: Hypertension News From Medical News Today [2014.07.04]
Women with long-term high blood pressure (hypertension) appear to be at an increased risk for the skin condition psoriasis, and long-term use of beta (β)-blocker medication to treat hypertension...

Risk of hypertension increased in pregnancies resulting from egg donation
Source: Fertility News From Medical News Today [2014.07.02]
With an ever-ageing female patient population, egg donation is an increasingly common treatment in infertility.

more news >>

Published Studies Related to Micardis HCT (Telmisartan / Hydrochlorothiazide)

Comparison of therapies between fixed-dose telmisartan/hydrochlorothiazide and losartan/hydrochlorothiazide in patients with mild to moderate hypertension. [2009.01]
Among angiotensin receptor blockers (ARBs), telmisartan is suggested to function as a partial agonist of peroxisome proliferator-activated receptor-gamma (PPAR gamma) and to improve lipid and glucose metabolism. Clinical benefits of telmisartan over other ARBs may be apparent in combination with diuretics, which have harmful influences on lipid and glucose metabolism...

The safety profile of telmisartan as monotherapy or combined with hydrochlorothiazide: a retrospective analysis of 50 studies. [2008.06]
BACKGROUND: To compare the tolerability and safety of telmisartan +/- hydrochlorothiazide (HCTZ)... CONCLUSION: The consolidated data show that telmisartan +/- HCTZ are well tolerated in patients of all ages and have placebo-like tolerabilities.

Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial. [2008.02]
In 2004-2005, the antihypertensive effects of telmisartan 80 mg versus valsartan 160 mg combined with hydrochlorothiazide 25 mg were assessed in a large placebo-controlled trial in patients with stages 1 and 2 hypertension and demonstrated that both agents were highly effective in lowering blood pressure (BP) compared with placebo and that telmisartan lowered BP significantly greater than valsartan...

Nilotinib. [2008]
Nilotinib is an orally administered BCR-ABL tyrosine kinase inhibitor that has shown good clinical efficacy in imatinib-resistant or -intolerant, Philadelphia chromosome-positive, chronic myeloid leukaemia (CML) in a phase I/II trial. The phase I component of the trial established the dosage regimen used in the phase II part of the trial, which included several arms...

Effect of telmisartan/hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients. [2006.03]
The aim of this study was to compare the effects of telmisartan/hydrochlorothiazide (HCTZ) vs lisinopril/HCTZ combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients. A total of 160 patients, 76 men and 84 women, aged 61-75 years, with sitting diastolic blood pressure (DBP)>90 mmHg and <110 mmHg and systolic blood pressure (SBP)>140 mmHg were randomized to receive temisartan 80 mg/HCTZ 12.5 mg o.d...

more studies >>

Clinical Trials Related to Micardis HCT (Telmisartan / Hydrochlorothiazide)

Telmisartan80mg/hydrochlothiazide12.5mg (Micardis Plus) ABPM Study in China [Completed]
to evaluate the trough and peak effect of once daily MICARDIS PLUS? (Telmisartan 80mg / hydrochlorot hiazide 12. 5 mg) by 24 ABPM in patients with mild to moderate essential hypertension

INNOVATION Study - Telmisartan (Micardis?) in Incipient Diabetic Nephropathy [Completed]
The aim of this study is to compare the preventive effect of Telmisartan (Micardis?) versus placebo control on the transition to overt nephropathy in patients with diabetic nephropathy manifesting mic roalbuminuria associated with type II diabetes, and to evaluate the efficacy and safety of Telmisart an (Micardis?, Gliosartan?, Kinzal?, Kinzalmono?, Predxal?, Pritor?, Samertan?, Telmisartan?) for di abetic nephropathy patients.

PRO-POWER: Hypertension With Risk Factors for a Duration of 24 Weeks With Micardis 80mg/Micardis Plus 80mg/12.5mg [Recruiting]
PRO-POWER is an observational cohort study for a period of 24 weeks. All recruited patients will have essential hypertension. In addition, the patients will have at least one other contributing risk factor for cardiovascular events. The study aims to evaluate the safety, efficacy and protection of Micardis 80mg/Micardis plus 80/12. 5mg from cardiovascular risks in patients with essential hypertension

CKD-828 Telmisartan Non-Responder Trial [Recruiting]
The aim of the present study is to evaluate the efficacy and safety of two dose combination of Telmisartan/S-Amlodipine (40/2. 5mg and 40/5mg) compared with telmisartan monotherapy (80mg) in hypertensive patients inadequately controlled by telmisartan monotherapy.

Telmisartan80/HCTZ25 Versus telmisartan80/HCTZ12.5 in Hypertension Not Responding to telmisartan80/HCTZ12.5 [Completed]
The primary objective of this trial is to demonstrate that a fixed dose combination of telmisartan 8 0 mg plus hydrochlorothiazide 25 mg (T80/H25) is superior in reducing blood pressure after eight wee ks compared with a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide 12. 5 mg (T80

/H12. 5) in patients who fail to respond to six weeks treatment with T80/H12. 5.

more trials >>

Reports of Suspected Micardis HCT (Telmisartan / Hydrochlorothiazide) Side Effects

Blood Pressure Increased (9)Dyspnoea (9)Hyponatraemia (9)Haematoma (8)Pollakiuria (8)Renal Failure Acute (7)Hypertension (7)Drug Ineffective (6)Injection Site Haemorrhage (6)Rales (6)more >>


Page last updated: 2014-07-24

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014